• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

J Infect Dis 2008 Jun 15;197(12):1662-8

Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, Rowland J, Rubin S, Safranek TJ, Bellini WJ, Dayan GH

Date, AA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Epidem Intelligence Serv, 1600 Clifton Rd,MS E-04, Atlanta, GA 30333 USA Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Epidem Intelligence Serv, Atlanta, GA 30333 USA Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA Univ Nebraska, Kearney, NE USA Two Rivers Publ Hlth Dept, Kearney, NE USA Univ Nebraska Med Ctr, Nebraska Publ Hlth Lab, Omaha, NE USA Nebraska Hlth & Human Serv Syst, Lincoln, NE USA US FDA, Bethesda, MD 20014 USA

Abstract

BACKGROUND: High attack rates among vaccinated young adults reported during the 2006 mumps outbreak in the United States heightened concerns regarding mumps vaccine failure. METHODS: Serum specimens from university students and staff were tested for mumps immunoglobulin (Ig) G by enzyme immunoassay (EIA). A subset of participants vaccinated for < or =5 years and > or =15 years were tested by neutralizing antibody (NA) assay. Persons seronegative by EIA were offered a third dose of measles-mumps-rubella vaccine (MMR3), and serum specimens were obtained 7-10 days and 2-3 months after its administration. RESULTS: Overall, 94% (95% confidence interval [CI], 91%-96%) of the 440 participants were seropositive. No differences existed in seropositivity rates by sex, age, age at receipt of the second dose of MMR vaccine (MMR2), or time since receipt of MMR2 (P = .568). The geometric mean titer (GMT) of NA among persons vaccinated with MMR2 during the previous 1-5 years was 97 (95% CI, 64-148), whereas, among those vaccinated > or =15 years before blood collection, the GMT was 58 (95% CI, 44-76) (P = .065). After MMR3, 82% (14/17) and 91% (10/11) seroconverted in 7-10 days and 2-3 months, respectively. CONCLUSIONS: Lower levels of NA observed among persons who received MMR2 > or =15 years ago demonstrates antibody decay over time. MMR3 vaccination of most seronegative persons marked the capacity to mount an anamnestic response.


Category: Journal Article
PubMed ID: #18419346
Entry Created: 2011-10-04 Entry Last Modified: 2012-08-29
Feedback
-
-